SciSparc Ltd.
SPRC
SciSparc Ltd., a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include SCI-110 for the treatment of Tourette syndrome, obstructive sleep apnea, and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of autism spectrum disorder and epilepsy. The company has an agreement wā¦ read more
Healthcare
Biotechnology
4 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$7.12
Price-18.16%
-$1.58
1Y
Price
Market Cap
$411.814k
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1703.5%
EBITDA Margin-2023.4%
Net Profit Margin-403.7%
Free Cash Flow Margin-1703.5%
EBITDA Margin-2023.4%
Net Profit Margin-403.7%
Free Cash Flow MarginRevenue
$856k
+104.8%
1y CAGR+54.6%
3y CAGR+47.5%
5y CAGREarnings
-$12.179m
-184.1%
1y CAGR-101.5%
3y CAGR-62.3%
5y CAGREPS
-$882.64
-4087.0%
1y CAGR-1328.6%
3y CAGR-976.5%
5y CAGRBook Value
$5.147m
$7.622m
Assets$2.475m
Liabilities$366k
DebtDebt to Assets
4.8%
-0.1x
Debt to EBITDAFree Cash Flow
-$4.137m
-88.5%
1y CAGR-7.1%
3y CAGR-43.0%
5y CAGRNo items found.
Press Releases
Statements and updates from the company